Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group has announced its plan to spin off Xuanzhu Biopharm and list it on the Main Board of the Stock Exchange, aiming to enhance financial flexibility and boost R&D capabilities. The company has also acquired an additional 3.6177% equity in Xuanzhu Biopharm for approximately RMB308 million, consolidating their influence in the biopharmaceutical sector. This strategic move is expected to strengthen Xuanzhu’s ability to access capital markets and support its growth, while allowing Sihuan to concentrate on expanding its medical aesthetics business.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
